In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo

Related Experiment Video

Updated: Jun 14, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.7K

Joseph H Friedman1

  • 1Butler Hospital/Alpert Medical School of Brown University, Providence, Rhode Island, USA (J.H.F.).

Annals of Internal Medicine
|September 2, 2024
PubMed
Abstract

Source Citation:

Meissner WG, Remy P, Giordana C, et al; LIXIPARK Study Group. Trial of lixisenatide in early Parkinson's disease. N Engl J Med. 2024;390:1176-1185. 38598572.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.7K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Related Experiment Videos

Last Updated: Jun 14, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.7K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.7K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

10.4K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

Articles linked to this work by shared authors, journal, and citation graph.

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026

True vignettes: interesting, illustrative examples of behavioral abnormalities in people with Parkinson's disease.

Arquivos de neuro-psiquiatria·2026

Cross-Dataset Evaluation of an Automated Video-Based Model for Detecting Tardive Dyskinesia Using the Clinician's Tardive Inventory: Validation Study.

JMIR mental health·2026

Prodromal Peripheral Immune Cell Profile in Drug-Induced Parkinsonism Relative to Parkinson's Disease.

Movement disorders clinical practice·2025

Treating psychosis in people with Parkinson's disease.

Expert opinion on drug safety·2025

Episodic Coma in Lewy Body Disorders: An Observational Report.

The Neurohospitalist·2024

Laparoscopic Versus Open Liver Resection for Colorectal Liver Metastases : An Individual Participant Data Meta-analysis of Four Randomized Clinical Trials.

Annals of internal medicine·2026

Obesity and Cancer Risk in Young Adults in Korea : A Nationwide Health Screening Cohort Study.

Annals of internal medicine·2026

Impact of Unrestricted Artificial Intelligence Scribe Deployment in a Single Health System on Clinician Workload and Productivity : A Quality Improvement Study.

Annals of internal medicine·2026

TTPdb: a comprehensive database of targeted therapeutic peptides.

Nucleic acids research·2026

Genetic and genomic medicine across the lung transplant continuum: inherited disease, pharmacogenomics, and molecular surveillance.

Current opinion in organ transplantation·2026

Tiny Lungs, Big Challenge: The Treatment Landscape of Pediatric Tuberculosis.

Pulmonary medicine·2026

PSMA Theranostics for Prostate Cancer: Evidence, Pitfalls, and Implementation in Japan.

International journal of urology : official journal of the Japanese Urological Association·2026

Artificial Cells and Biomimetic Cells: Intelligent Systems Driving a Paradigm Shift in Drug Discovery and Delivery.

Advanced healthcare materials·2026

Pharmacological inhibition of METTL1 as a therapy against solid and blood cancers.

Nature·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us